Tarenflurbil is an investigational drug that was studied in patients with mild Alzheimer's disease. It is a selective amyloid lowering agent (SALA) that reduces levels of the toxic peptide amyloid... Aβ42 is the primary initiator of neurotoxicity and amyloid plaque development in the brains of Alzheimer's disease patients.
- Mechanism
- Curator reviewed
MPC-7869 is not an inhibitor of cyclooxygenase enzymes (COX-1 and COX-2). The compound modulates the signal transduction and transcription activation pathways associated with nuclear factor kappaB (NFkappaB), a principle transcription factor in the expression of many molecules involved in cell growth, cell death and inflammation. In addition, MPC-7869 has recently been shown to modulate gamma-secretase and selectively lower levels of Abeta42 peptide in vitro and in vivo, and to reduce amyloid pathology in the brain. MPC-7869 has an excellent safety profile and is very potent in animal models of cancer and Alzheimer's disease. In transgenic mouse studies, MPC-7869 reduced brain amyloid levels and prevented memory loss.
- Primary indication
- Investigated for use/treatment in alzheimer's disease and prostate cancer.Curator reviewed
- Formula / weight
- C15H13FO2 · 244.2609 g/mol (avg)
- Also known as
- (R)-flurbiprofen
- Code names
- E-7869 · MPC-7869
Resolves to
SYTBZMRGLBWNTM-SNVBAGLBSA-NSMILESC[C@@H](C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1What you can answer from here — as of January 29, 2025
Which drugs share a target with Tarenflurbil, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account